After obtaining a Master’s degree in Life Sciences from the “École Pratique des Hautes Études” (Paris Sciences and Letters University) in 2022, Marina Villaverde has just started a PhD thesis. Through the collaboration between the Institute for Regenerative Medicine and Biotherapies and HCS Pharma, this PhD work will focus on the development of a new osteoarthritic model in vitro with the 3D BIOMIMESYS® technology in order to identify new therapies for this common and so far uncured disease.
Biomimesys
Meet HCS PHARMA at Forum Labo!
We will be pleased to meet you in Paris from the 28th to 30th of March. Join Thierry DE CATHEU Business Director, Mathieu LAOUENAN Chief Commercial Officer, Paul COUVREUR and Rita HIEN Junior Business Developpers. Read more…
0 Comments